Phase Ib/II study of TTI-621 in patients with relapsed/refractory diffuse large B-cell lymphoma combined with anti-PD-1
Latest Information Update: 05 May 2021
At a glance
- Drugs Ontorpacept (Primary) ; Programmed cell death-1 ligand-1 inhibitors
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 05 May 2021 New trial record
- 28 Apr 2021 According to a Trillium Therapeutics media release, the company plans to initiate this study in 4Q 2021 to 1H 2022.
- 28 Apr 2021 According to a Trillium Therapeutics media release, this is an investigator-sponsored trial at Mayo Clinic.